Evidence map›Paper›PMID 39568325›Full record

ArticleFuture medicinal chemistry2024

New 4-amino-3-chloro benzoate ester derivatives as EGFR inhibitors: synthesis, in silico and biological analyses.

Nedaa A Abd Al Rahim, Ammar A Razzak Mahmood, Lubna H Tahtamouni, Mai F AlSakhen, Salem R Yasin, Abdulrahman M Saleh

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nedaa A Abd Al RahimDepartment of Pharmaceutical Chemistry, College of Pharmacy, University of Baghdad, Baghdad, Iraq.
Ammar A Razzak MahmoodDepartment of Pharmaceutical Chemistry, College of Pharmacy, University of Baghdad, Baghdad, Iraq.ORCID 0000-0002-4915-417X
Lubna H TahtamouniDepartment of Biology and Biotechnology, Faculty of Science, The Hashemite University, Zarqa, Jordan.ORCID 0000-0001-8024-1944
Mai F AlSakhenDepartment of Biology and Biotechnology, Faculty of Science, The Hashemite University, Zarqa, Jordan.
Salem R YasinDepartment of Biology and Biotechnology, Faculty of Science, The Hashemite University, Zarqa, Jordan.
Abdulrahman M SalehDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimThe main goal of this study was to synthesize new derivatives of 4-amino-3-chloro benzoate ester, including 1,3,4-oxadiazole derivatives ( MATERIALS &

methodsThe new derivatives were characterized using various spectroscopic techniques. Docking studies were used to investigate the binding patterns to EGFR, and the anti-proliferative properties were tested in vitro.

resultsIn silico analysis showed that the hydrazine-1-carbothioamide derivatives (

conclusionThe results of this study show that compound

Indexed as

ChlorobenzenesErbB ReceptorsEsterspara-AminobenzoatesTyrosine Kinase InhibitorsApoptosisCaspase 3Caspase 8Cell Line, TumorComputer SimulationEnzyme ActivationHumans4-amino-3-chlorobenzoic acidCaspase 3Caspase 8ChlorobenzenesEGFR protein, humanErbB ReceptorsEsterspara-AminobenzoatesTyrosine Kinase Inhibitorsanti-proliferationBenzoic aciddocking studiesEGFR tyrosine kinaseerlotinib

Identifiers

PMID39568325
PMCPMC11730846

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.